Ultragenyx Pharmaceutical Inc. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 1/100
What the filing says
Form 8-K filed 2026-10-14 reporting entry into a material definitive agreement (Item 1.01). No substantive details of counterparty, amount, terms, or business impact are present in the text provided—only the SEC filing metadata and document manifest are shown.
Why this rating
Cannot assess significance without actual agreement terms, counterparty, or financial details. Filing metadata alone is insufficient for evaluation.
Extracted items
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.